Akada M, Harada K, Negishi M, Katoh H. (2014) EphB6 promotes anoikis by modulating EphA2 signaling. Cell. Signal., 26, 2879–2884.
Amato KR, Wang S, Tan L, Hastings AK, Song W, Lovely CM, Meador CB, Ye F, Lu P, Balko JM, Colvin DC, Cates JM, Pao W, Gray NS, Chen J. (2016) EPHA2 blockade overcomes acquired resistance to EGFR kinase inhibitors in lung cancer. Cancer Res., 76, 305–318.
Anjum R, Blenis J. (2008) The RSK family of kinases: emerging roles in cellular signaling. Nat. Rev. Mol. Cell Biol., 9, 747–758.
Barquilla A, Lamberto I, Noberini R, Heynen-Genel S, Brill LM, Pasquale EB. (2016) Protein kinase A can block EphA2 receptor-mediated cell repulsion by increasing EphA2 S897 phosphorylation. Mol. Biol. Cell, 27, 2757–2770.
Bermudez O, Marchetti S, Pagès G, Gimond C. (2008) Post-translational regulation of the ERK phosphatase DUSP6/MKP3 by the mTOR pathway. Oncogene, 27, 3685-3691
Bhagatte Y, Lodwick D, Storey N. (2012) Mitochondrial ROS production and subsequent ERK phosphorylation are necessary for temperature preconditioning of isolated ventricular myocytes. Cell Death Dis., 3, e345
Binda E, Visioli A, Giani F, Lamorte G, Copetti M, Pitter KL, Huse JT, Cajola L, Zanetti N, DiMeco F, De Filippis L, Mangiola A, Maira G, Anile C, De Bonis P, Reynolds BA, Pasquale EB, Vescovi AL. (2012) The EphA2 receptor drives self-renewal and tumorigenicity in stem-like tumor-propagating cells from human glioblastomas. Cancer Cell, 22, 765–780.
Boyd AW, Bartlett PF, Lackmann M. (2014) Therapeutic targeting of EPH receptors and their ligands. Nat. Rev. Drug Discov., 13, 39–62.
Cairns RA, Harris IS, Mak TW. (2011) Regulation of cancer cell metabolism. Nat. Rev. Cancer, 11, 85–95.
Chung WJ, Lyons SA, Nelson GM, Hamza H, Gladson CL, Gillespie GY, Sontheimer H. (2005) Inhibition of cystine uptake disrupts the growth of primary brain tumors. J. Neurosci., 25, 7101–7110.
Conrad M, Sato H. (2012) The oxidative stress-inducible cystine/glutamate antiporter, system xc-: cystine supplier and beyond. Amino Acids, 42, 231–246.
Conrad M, Kagan VE, Bayir H, Pagnussat GC, Head B, Traber MG, Stockwell BR. (2018) Regulation of lipid peroxidation and ferroptosis in diverse species. Genes Dev., 32, 602–619.
Day BW, Stringer BW, Boyd AW. (2014) Eph receptors as therapeutic targets in Glioblastoma. Br. J. Cancer, 111, 1255–1261.
Dixon SJ, Lemberg KM, Lamprecht MR, Skouta R, Zaitsev EM, Gleason CE, Patel DN, Bauer AJ, Cantley AM, Yang WS, Morrison III B, Stockwell BR. (2012) Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell, 149, 1060–1072.
Dornier E, Rabas N, Mitchell L, Novo D, Dhayade S, Marco S, Mackay G, Sumpton D, Pallares M, Nixon C, Blyth K, Macpherson IR, Rainero E, Norman JC. (2017) Glutaminolysis drives membrane trafficking to promote invasiveness of breast cancer cells. Nat. Commun., 8, 2255.
Eckert A, Böck BC, Tagscherer KE, Haas TL, Grund K, Sykora J, Herold-Mende C, Ehemann V, Hollstein M, Chneiweiss H, Wiestler OD, Walczak H, Roth W. (2008) The PEA-15/PED protein protects glioblastoma cells from glucose deprivation-induced apoptosis via the ERK/MAP kinase pathway. Oncogene, 27, 1155–1166.
Finkel T. (2011) Signal transduction by reactive oxygen species. J. Cell Biol., 194, 7–15.
Goji T, Takahara K, Negishi M, Katoh H. (2017) Cystine uptake through the cystine/ glutamate antiporter xCT triggers glioblastoma cell death under glucose deprivation. J. Biol. Chem., 292, 19721–19732.
Graham NA, Tahmasian M, Kohil B, Komisopoulou E, Zhu M, Vivanco I, Teitell MA, Wu H, Ribas A, Lo RS, Mellinghoff IK, Mischel PS, Graeber TG. (2012) Glucose deprivation activates a metabolic and signaling amplification loop to cell death. Mol. Syst. Biol., 8, 589.
Graves PR, Din SU, Ashamalla M, Ashamalla H, Gilbert TSK, Graves LM. (2017) Ionizing radiation induces EphA2 S897 phosphorylation in a MEK/ERK/RSK-dependent manner. Int. J. Radiat. Biol., 93, 929–936.
Hamanaka RB, Chandel NS. (2010) Mitochondrial reactive oxygen species regulate cellular signaling and dictate biological outcomes. Trends Biochem. Sci., 35, 505–513.
Hamaoka Y, Negishi M, Katoh H. (2016) EphA2 is a key effector of the MEK/ERK/RSK pathway regulating glioblastoma cell proliferation. Cell. Signal., 28, 937–945.
Hamaoka Y, Negishi M, Katoh H. (2018) Tyrosine kinase activity of EphA2 promotes its S897 phosphorylation and glioblastoma cell proliferation. Biochem. Biophys. Res. Commun., 499, 920–926.
Hanahan D, Weinberg RA. (2011) Hallmarks of cancer: the next generation. Cell, 144, 646-674.
Harada K, Negishi M, Katoh H. (2015) HGF-induced serine 897 phosphorylation of EphA2 regulates epithelial morphogenesis of MDCK cells in 3D culture. J. Cell Sci., 128, 1912–1921.
Hay N. (2016) Reprogramming glucose metabolism in cancer: can it be exploited for cancer therapy? Nat. Rev. Cancer, 16, 635–649.
Holmström KM, Finkel T. (2014) Cellular mechanisms and physiological consequences of redox-dependent signaling. Nat. Rev. Mol. Cell Biol., 15, 411–421.
Jeon SM, Chandel NS, Hay N. (2012) AMPK regulates NADPH homeostasis to promote tumour cell survival during energy stress. Nature, 485, 661–665.
Katoh Y, Michisaka S, Nozaki S, Funabashi T, Hirano T, Takei R, Nakayama K. (2017) Practical method for targeted disruption of cilia-related genes by using CRISPR/ Cas9-mediated homology-independent knock-in system. Mol. Biol. Cell, 28, 898–906.
Kawai H, Kobayashi M, Hiramoto-Yamaki N, Harada K, Negishi M, Katoh H. (2013) Ephexin4-mediated promotion of cell migration and anoikis resistance is regulated by serine 897 phosphorylation of EphA2. FEBS Open Bio, 3, 78–82.
Kim MJ, Park IJ, Yun H, Kang I, Choe W, Kim SS, Ha J. (2010) AMP-activated protein kinase antagonizes pro-apoptotic extracellular signal-regulated kinase activation by inducing dual-specificity protein phosphatases in response to glucose deprivation in HCT116 carcinoma cells. J. Biol. Chem., 285, 14617–14627.
Koppula P, Zhang Y, Shi J, Li W, Gan B. (2017) The glutamate/cystine antiporter SLC7A11/xCT enhances cancer cell dependency on glucose by exporting glutamate. J. Biol. Chem., 292, 14240–14249.
Koppula P, Zhang Y, Zhuang L, Gan B. (2018) Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer Commun., 38, 12.
Lee YJ, Galoforo SS, Berns CM, Chen JC, Davis BH, Sim JE, Corry PM, Spitz DR. (1998) Glucose deprivation-induced cytotoxicity and alterations in mitogenactivated protein kinase activation are mediated by oxidative stress in multidrugresistant human breast carcinoma cells. J. Biol. Chem., 273, 5294–5299.
Lewerenz J, Hewett SJ, Huang Y, Lambros M, Gout PW, Kalivas PW, Massie A, Smolders I, Methner A, Pergande M, Smith SB, Ganapathy V, Maher P. (2013) The cystine/glutamate antiporter system xc- in health and disease: from molecular mechanisms to novel therapeutic opportunities. Antioxid. Redox Signal., 18, 522–555.
Liu F, Park PJ, Lai W, Maher E, Chakravarti A, Durso L, Jiang X, Yu Y, Brosius A, Thomas M, Chin L, Brennan C, DePinho RA, Kohane I, Carroll RS, Black PM, Johnson MD. (2006) A genome-wide screen reveals functional gene clusters in the cancer genome and identified EphA2 as a mitogen in glioblastoma. Cancer Res., 66, 10815–10823.
Lunt SY, Vander Heiden MG. (2011) Aerobic glycolysis: meeting the metabolic requirements of cell proliferation. Annu. Rev. Cell Dev. Biol., 27, 441–464.
Lyons SA, Chung WJ, Weaver AK, Ogunrinu T. (2007) Autocrine glutamate signaling promotes glioma cell invasion. Cancer Res., 67, 9463–9471.
Miao H, Li DQ, Mukherjee A, Guo H, Petty H, Cutter J, Basilion JP, Sedor J, Wu J, Danielpour D, Sloan AE, Cohen MI, Wang B. (2009) EphA2 mediates ligand-dependent inhibition and ligand-independent promotion of cell migration and invasion via a reciprocal regulatory loop with Akt. Cancer Cell, 16, 9–20.
Miao H, Gale NW, Guo H, Qian J, Petty A, Kaspar J, Murphy AJ, Valenzuela DM, Yancopoulos G, Hambardzumyan D, Lathia JD, Rich JN, Wang B. (2014) EphA2 promotes infiltrative invasion of glioma stem cells in vivo through cross-talk with Akt and regulates stem cell properties. Oncogene, 34, 558–567.
Nakada M, Hayashi Y, Hamada J. (2011) Role of Eph/ephrin tyrosine kinase in malignant Glioma. Neuro-Oncology, 13, 1163–1170.
Pasquale EB. (2010) Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat. Rev. Cancer, 10, 165–180.
Polewski MD, Reveron-Thornton RF, Cherryholmes GA, Marinov GK, Cassady K, Aboody KS. (2016) Increased expression of system xc- in glioblastoma confers an altered metabolic state and temozolomide resistance. Mol. Cancer Res., 14, 1229–1242.
Sabharwal SS, Schumacker PT. (2014) Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles' heel? Nat. Rev. Cancer, 14, 709–721.
Savaskan NE, Heckel A, Hahnen E, Engelhorn T, Doerfler A, Ganslandt O, Nimsky C, Buchfelder M, Eyüpoglu IY. (2008) Small interfering RNA-mediated xCT silencing in gliomas inhibits neurodegeneration and alleviates brain edema. Nat. Med., 14, 629–632.
Shin CS, Mishra P, Watrous JD, Carelli V, D'Aurelio M, Jain M, Chan DC. (2017) The glutamate/cystine xCT antiporter antagonaizes glutamine metabolism and reduces nutrient flexibility. Nat. Commun., 8, 15074.
Sleire L, Skeie BS, Netland IA, Førde HE, Dodoo E, Selheim F, Leiss L, Heggdal JI, Pedersen PH, Wang J, Enger PØ. (2015) Drug repurposing: sulfasalazine sensitizes glioma to gamma knife radiosurgery by blocking cystine uptake through system Xc-, leading to glutathione depletion. Oncogene, 34, 5951–5959.
Stockwell BR, Angeli JPF, Bayir H, Bush AI, Conrad M, Dixon SJ, Fulda S, Gascón S, Hatzios SK, Kagan VE, Noel K, Jiang X, Linkermann A, Murphy ME, Overholtzer M, Oyagi A, Pagnussat GC, Park J, Ran Q, Rosenfeld CS, Salnikow K, Tang D, Torti FM, Torti SV, Toyokuni S, Woerpel KA, Zhang DD. (2017) Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. Cell, 171, 273–285.
Takeuchi S, Wada K, Toyooka T, Shinomiya N, Shimazaki H, Nakanishi K, Nagatani K, Otani N, Osada H, Uozumi Y, Matsuo H, Nawashiro H. (2013) Increased xCT expression correlates with tumor invasion and outcome in patients with glioblastoma. Neurosurgery, 72, 33–41.
Tan WQ, Wang K, Lv DY, Li PF. (2008) Foxo3a inhibits cardiomyocyte hypertrophy through transactivating catalase. J. Biol. Chem., 283, 29730-29739
Tsuchihashi K, Okazaki S, Ohmura M, Ishikawa M, Sampetrean O, Onishi N, Wakimoto H, Yoshikawa M, Seishima R, Iwasaki Y, Morikawa T, Abe S, Takao A, Shimizu M, Masuko T, Nagane M, Furnari FB, Akiyama T, Suematsu M, Baba E, Akashi K, Saya H, Nagano O. (2016) The EGF receptor promotes the malignant potential of glioma by regulating amino acid transport system xc(-). Cancer Res., 76, 2954–2963.
Wang LF, Fokas E, Bieker M, Rose F, Rexin P, Zhu Y, Pagenstecher A, Engenhart- Cabillic R, An HX. (2008) Increased expression of EphA2 correlates with adverse outcome in primary and recurrent glioblastoma multiforme patients. Oncol. Rep., 19, 151–156.
Wykosky J, Debinski W. (2008) The EphA2 receptor and ephrinA1 ligand in solid tumors: function and therapeutic targeting. Mol. Cancer Res., 6, 1795–1806.
Wykosky J, Gibo DM, Stanton C, Debinski W. (2005) EphA2 as a novel molecular markaer and target in glioblastoma multiform. Mol. Cancer Res., 3, 541–551.
Zhang J, Pavlova NN, Thompson CB. (2017) Cancer cell metabolism: the essential role of the nonessential amino acid, glutamine. EMBO J., 36, 1302–1315.
Zhou Y, Yamada N, Tanaka T, Hori T, Yokoyama S, Hayakawa Y, Yano S, Fukuoka J, Koizumi K, Saiki I, Sakurai H. (2015) Crucial roles of RSK in cell motility by catalyzing serine phosphorylation of EphA2. Nat. Commun., 6, 8679.
Zhou Y, Sakurai H. (2017) Emerging and diverse functions of the EphA2 noncanonical pathway in cancer progression. Biol. Pharm. Bull., 40, 1616–1624.
論文の公開元へ
